CSR Program: Drugs for Neglected Disease Initiative | Takeda Pharmaceuticals
Expanding neglected patient's access to quality diagnosis and treatment in disease-endemic countries
Equipping facilities with safe, effective tools, training primary health workers and supporting community awareness and behaviors
The Program
Partner: DNDi(Drugs for Neglected Diseases initiative)
Budget: 1 billion yen
Term: 5 years
Launch: 2019
Area: 16 countries accross Africa, Asia and South America
Visit the DNDi website
Over one billion people, including 500 million children, are affected by neglected tropical diseases (NTDs), a group of diseases that disproportionally prevail in tropical and subtropical countries. DNDi targets five NTDs: sleeping sickness, Chagas disease, leishmaniasis, onchocerciasis and mycetoma. These are characterized by significant morbidity and/or mortality and have been prioritized due to the current limited availability and accessibility of effective diagnostic and treatment.
Have more questions?
Contact us if you'd like more information about our Global CSR Program.